A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer (Wang et al., Biochemical Pharmacology, 2021)

SP101 is a novel EGFR inhibitor that suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer (NSCLC). SP101 provides a new class EGFR inhibitor by blocking survivin to overcome drug resistance of gefitinib for the NSCLC therapy.

Click here to read more

Selective Autophagy Pathway of Nanoparticles and Nanodrugs: Drug Delivery and Pathophysiological Effects (Raj et al., Advanced Therapeutics, 2020)

這張圖片的 alt 屬性值為空,它的檔案名稱為 %E6%88%AA%E5%9C%96-2020-07-03-13.16.50-2.png

The selective autophagy of nanoparticles and nanodrugs occurs through binding to ubiquitinated proteins, autophagy receptors, and LC3, the formation of nanoparticulosomes, and their delivery to lysosomes. We termed this processing of nanoparticles and nanodrugs through selective autophagy pathways “Nanoparticulophagy”.

Click here to read more